BioXcel Therapeutics Inc (NASDAQ:BTAI) CEO Vimal Mehta Buys 2,983 Shares

BioXcel Therapeutics Inc (NASDAQ:BTAI) CEO Vimal Mehta bought 2,983 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was bought at an average cost of $8.64 per share, for a total transaction of $25,773.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vimal Mehta also recently made the following trade(s):

  • On Tuesday, August 13th, Vimal Mehta bought 1,000 shares of BioXcel Therapeutics stock. The stock was bought at an average cost of $8.75 per share, for a total transaction of $8,750.00.

NASDAQ:BTAI traded up $0.48 during trading hours on Friday, hitting $9.15. The company had a trading volume of 8,309 shares, compared to its average volume of 64,247. The company has a market capitalization of $134.49 million, a PE ratio of -6.93 and a beta of 3.02. The stock has a 50-day moving average price of $10.34 and a 200 day moving average price of $9.96. BioXcel Therapeutics Inc has a 52 week low of $2.41 and a 52 week high of $12.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.93 and a quick ratio of 3.93.



BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.02). Analysts anticipate that BioXcel Therapeutics Inc will post -2.22 EPS for the current fiscal year.

A number of research analysts have commented on BTAI shares. HC Wainwright set a $25.00 price target on shares of BioXcel Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 5th. Zacks Investment Research cut shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Finally, ValuEngine upgraded shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th.

Large investors have recently added to or reduced their stakes in the stock. Capital Investment Advisory Services LLC purchased a new position in BioXcel Therapeutics during the second quarter valued at $53,000. Charles Schwab Investment Management Inc. purchased a new position in BioXcel Therapeutics during the second quarter valued at $138,000. Bank of New York Mellon Corp purchased a new position in BioXcel Therapeutics during the second quarter valued at $198,000. Creative Planning purchased a new position in BioXcel Therapeutics during the first quarter valued at $302,000. Finally, Northern Trust Corp lifted its position in BioXcel Therapeutics by 247.7% during the second quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock valued at $481,000 after buying an additional 31,218 shares during the period. Institutional investors and hedge funds own 16.03% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Further Reading: Rule of 72

Insider Buying and Selling by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.